Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Taking targeted autoimmune therapies to the next level

Clinical Research

The TRIAD project has been featured on the HORIZON 2020 website in an article entitled 'Taking targeted autoimmune therapies to the next level.'

The Transplantation Research Immunology Group (TRIG) was a consortium partner in TRIAD, an EU funded project which led to the preclinical development of the novel drug FR104. The drug is now going through clinical trials, leading, it is hoped, to eventual commercialisation.  

Read the full article.

Categories

Similar stories

ASPI honours ProtecT Trial for pioneering research demonstrating the safety of active surveillance

The ProtecT Trial has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award for game-changing research in the development of the Active Surveillance approach to managing low-risk prostate cancer.

Global Surgery DPhil student wins best presentation prize at BAPS 70th Anniversary Congress

The second NDS Student Symposium held